Moreover, genetic manipulation of NK cells to express CD33 chimeric antigen receptors, although showed improved cytotoxic activity against leukemic cells in vitro, did not show any clinical efficacy for AML patients [50]. Here, CD33 is linked to acute myeloid leukemia.